Companies › Jade Biosciences
2 active drug programs in 5 registered trials: 3 Phase 1, 1 Phase 3, 1 Phase 2; Genitourinary, Other, Immunology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JADE101 | – | Phase 3 | IgA Nephropathy (IgAN); IgA Nephropathy; Healthy Volunteers; Healthy Volunteers (HV) | May 2027 |
| JADE201 | – | Phase 1 | Rhematoid Arthritis | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07059312 | JADE101 | Phase 1 | Healthy Volunteers | Other | Oct 2026 |
| NCT07525947 | JADE101 | Phase 1 | Healthy Volunteers (HV) | Other | May 2027 |
| NCT07533955 | JADE201 | Phase 1 | Rhematoid Arthritis | Immunology | Oct 2027 |
| NCT07541287 | JADE101 | Phase 2 | IgA Nephropathy | Genitourinary | Jan 2029 |
| NCT07902817 | JADE101 | Phase 3 | IgA Nephropathy (IgAN) | Genitourinary | Jun 2029 |
Cash and short-term investments of $461m on 2026-06-30; operating cash outflow about $137m a year; runway about 40 months at that burn, to Nov 2029; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 13 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Akebia Therapeutics Sagimet Biosciences Kymera Therapeutics Oruka Therapeutics Abivax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.